Victory Capital Management Inc. Has $22.26 Million Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Victory Capital Management Inc. lessened its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 3.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 723,297 shares of the specialty pharmaceutical company’s stock after selling 24,974 shares during the period. Victory Capital Management Inc.’s holdings in Collegium Pharmaceutical were worth $22,263,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. SummerHaven Investment Management LLC raised its holdings in Collegium Pharmaceutical by 1.1% in the 4th quarter. SummerHaven Investment Management LLC now owns 34,034 shares of the specialty pharmaceutical company’s stock worth $1,048,000 after acquiring an additional 368 shares during the period. Russell Investments Group Ltd. lifted its position in shares of Collegium Pharmaceutical by 26.9% during the 4th quarter. Russell Investments Group Ltd. now owns 32,073 shares of the specialty pharmaceutical company’s stock worth $987,000 after purchasing an additional 6,796 shares during the last quarter. New York State Common Retirement Fund boosted its stake in Collegium Pharmaceutical by 1,475.5% during the 4th quarter. New York State Common Retirement Fund now owns 201,112 shares of the specialty pharmaceutical company’s stock valued at $6,190,000 after purchasing an additional 188,347 shares during the period. Illinois Municipal Retirement Fund grew its holdings in Collegium Pharmaceutical by 2.1% in the 4th quarter. Illinois Municipal Retirement Fund now owns 19,879 shares of the specialty pharmaceutical company’s stock valued at $612,000 after buying an additional 411 shares during the last quarter. Finally, Federated Hermes Inc. increased its position in Collegium Pharmaceutical by 76.0% in the 4th quarter. Federated Hermes Inc. now owns 212,768 shares of the specialty pharmaceutical company’s stock worth $6,549,000 after buying an additional 91,911 shares during the period.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on COLL. Piper Sandler restated an “overweight” rating and issued a $39.00 price objective (up previously from $37.00) on shares of Collegium Pharmaceutical in a research note on Friday, February 23rd. Needham & Company LLC restated a “buy” rating and set a $40.00 price objective on shares of Collegium Pharmaceutical in a report on Thursday, April 11th. Truist Financial increased their target price on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, February 26th. Finally, StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 1st. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.

Collegium Pharmaceutical Stock Performance

NASDAQ COLL opened at $38.06 on Thursday. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of 32.25 and a beta of 1.06. The company has a current ratio of 1.17, a quick ratio of 1.10 and a debt-to-equity ratio of 2.48. Collegium Pharmaceutical, Inc. has a 1-year low of $20.83 and a 1-year high of $40.95. The company has a 50 day moving average of $37.61 and a 200-day moving average of $32.17.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.25. The firm had revenue of $149.75 million during the quarter, compared to the consensus estimate of $147.66 million. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. On average, equities analysts forecast that Collegium Pharmaceutical, Inc. will post 5.63 earnings per share for the current fiscal year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.